Article info
PDFClinical
Original research
Single-tablet regimen of emtricitabine/tenofovir disoproxil fumarate plus cobicistat-boosted elvitegravir increase adherence for HIV postexposure prophylaxis in sexual assault victims
- Correspondence to Dr Stefano Malinverni, Emergency Medicine, CHU Saint-Pierre, Bruxelles, Belgium; stefano_malinverni{at}stpierre-bru.be
Citation
Single-tablet regimen of emtricitabine/tenofovir disoproxil fumarate plus cobicistat-boosted elvitegravir increase adherence for HIV postexposure prophylaxis in sexual assault victims
Publication history
- Received July 22, 2020
- Revised September 17, 2020
- Accepted September 27, 2020
- First published October 26, 2020.
Online issue publication
July 19, 2021
Article Versions
- Previous version (26 October 2020).
- You are viewing the most recent version of this article.
Supplementary Data
This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.